• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Ball Bryan

    4/15/26 7:59:03 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WHWK alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BALL BRYAN

    (Last)(First)(Middle)
    C/O WHITEHAWK THERAPEUTICS, INC.
    2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

    (Street)
    MORRISTOWN NEW JERSEY 07960

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Whitehawk Therapeutics, Inc. [ WHWK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    See remarks
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/13/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock04/13/2026S(1)26,389D$3.46489,566D
    Common Stock04/14/2026S(1)92,460D$3.64397,106D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
    Remarks:
    Chief Technical Operations Officer and SVP, Manufacturing Operations
    /s/ Stephen Rodin, as Attorney-in-Fact04/15/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $WHWK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WHWK

    DatePrice TargetRatingAnalyst
    2/5/2026$6.00Outperform
    Oppenheimer
    More analyst ratings

    $WHWK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Giacobello Scott M.

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    4/17/26 4:53:19 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ball Bryan

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    4/15/26 7:59:03 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ball Bryan

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    4/13/26 8:34:27 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    SEC Filings

    View All

    SEC Form S-8 filed by Whitehawk Therapeutics Inc.

    S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    3/12/26 4:49:14 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Whitehawk Therapeutics Inc.

    10-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    3/12/26 4:12:28 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    3/12/26 8:02:47 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

    Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platformTumor regressions observed across various cancer models at low single‑digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC)Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026MORRISTOWN, N.J., April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug c

    4/19/26 6:00:00 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

    MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.About Whitehawk TherapeuticsWhitehawk Therapeutic

    4/16/26 4:05:00 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

    MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancerFindings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being explored in Phase 1 for advanced ovarian and endometrial cancersMORRISTOWN, N.J., April 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-wor

    4/10/26 7:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Whitehawk Therapeutics with a new price target

    Oppenheimer initiated coverage of Whitehawk Therapeutics with a rating of Outperform and set a new price target of $6.00

    2/5/26 9:40:37 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Leadership Updates

    Live Leadership Updates

    View All

    Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer

    Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy. "I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and

    12/1/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care